Cellectar Biosciences (CLRB)
(Real Time Quote from BATS)
$3.25 USD
+0.05 (1.56%)
Updated May 9, 2024 12:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
Cellectar Biosciences, Inc. [CLRB]
Reports for Purchase
Showing records 101 - 120 ( 120 total )
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Robust Data in MM - LPL/WM; Stock Dip Unwarranted; Reiterate Buy - $10 TP
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
CLR 131 Undervalued in DLBCL and MM - Potent Drug, Manageable Toxicity - Transferring Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Transferring Coverage Update - Biotechnology Sector
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Promising Clinical Update From CLOVER-1 Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Positive CLR131 Clinical Update in r/r MM at ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Potential Clinical Updates at ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Promising Interim Readout From CLOVER-1 at ESMO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Targeted Radiotherapy for Hematological Cancers
Provider: Roth Capital Partners, Inc.
Analyst: ISAACSON J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Multiple Clinical Updates in 2H19; Adjusting PT to $3.00 on Dilution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Phase 2 Clinical Updates in Hematologic Malignancies Expected by YE19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
New PDCs Looking to Upend the Heme-Onc Landscape; Initiate With Buy and $4.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Suspending Coverage
Provider: Griffin Securities, Inc.